15-Deoxy-Δ^12,14-Prostaglandin J₂ Modulates Lipopolysaccharide-Induced Chemokine Expression by Blocking Nuclear Factor-κB Activation via Peroxisome Proliferator Activated Receptor-γ-Independent Mechanism in Renal Tubular Epithelial Cells

Abstract

Background/Aims: Inflammation is an unavoidable milieu for renal tubular cells during the development of renal tubulointerstitial fibrosis. It has been demonstrated that chemokines including monocyte chemoattractant protein-1 (MCP-1) and IL-8 are related to tubulointerstitial lesions. 15d-PGJ₂ may modulate renal tubulointerstitial fibrosis progression via anti-inflammatory effects. However, no information is known about the effects of 15d-PGJ₂ on chemokine expression in human proximal renal tubular cells (HPTECs) under inflammation. Methods: In the present study, HPTECs (HK-2 cells) were stimulated with lipopolysaccharide (LPS) only, or preincubated with 15d-PGJ₂. IL-8 and MCP-1 expressions were determined by real-time PCR and ELISA. Nuclear factor-γB (NF-γB) location was detected by immunofluorescence analysis. The p-IKK, p-IγBa and p65/p50 were analyzed by immunoblotting. To investigate the mechanism of inhibitory effects of 15d-PGJ₂, the PPAR-γ gene was effectively silenced in HK-2 cells using specific siRNA. Results: The results showed that application of LPS significantly increased IL-8 and MCP-1 production. Phosphorylation of IγBa, IKK and nucleus translocation of NF-γB significantly increased in LPS-stimulated HK-2 cells. 15d-PGJ₂ downregulated LPS-induced IL-8 and MCP-1 production. Interestingly, in PPAR-γ-deficient HK-2 cells, 15d-PGJ₂ was still capable of inhibiting chemokines expression and attenuating phosphorylation of IγBa and nucleus translocation of NF-γB. Conclusion: Collectively, these results suggest that 15d-PGJ₂ exerts anti-inflammatory actions on HK-2 cells by attenuating chemokines expression. 15d-PGJ₂ inhibits chemokines expression via a PPAR-γ-independent way, which is related to block NF-γB pathway. Since NF-γB is an important regulator of the response of HPTECs to injury, PPAR-γ agonists may represent a key pharmacological target for ameliorating inflammation-associated tubulointerstitial fibrosis.

Bergenin, Acting as an Agonist of PPARγ, Ameliorates Experimental Colitis in Mice through Improving Expression of SIRT1, and Therefore Inhibiting NF-κB-Mediated Macrophage Activation

“…Up to now, the inhibition of NF-κB-p65 nuclear translocation is attributed to reduction of IκBα degradation or regulation of post-translational modification of NF-κB-p65 ( Lu et al, 2013 ; Lakshmi et al, 2014 ; Zhang et al, 2016 ). Our above-mentioned results indicated that bergenin only showed slight effect on IκBα degradation.…”

Inhibiting cancer cell hallmark features through nuclear export inhibition

“… 62 , 139–144 (3) Wortmannin and cyclopentenone prostaglandin (15d-PGJ2) were known for other functions before they were discovered as CRM1 inhibitors. 145 , 146 Fungal steroid metabolite wortmannin is a well-known PI3K inhibitor. 147 The cyclopentenone prostaglandin 15d-PGJ2 is an anti-inflammatory compound produced in the body.…”

PPARγ against Tumors by Different Signaling Pathways

“…15-deoxy-n-prostaglandin J2 (15d-PGJ 2 ), as the natural PPARγ ligand, has an anti-inflammatory effect on human peripheral blood monocytes [15]. 15d-PGJ 2 can attenuate the expression of chemokines by terminating the nuclear factor-κB (NF-κB) signal [16] or induce cell apoptosis [17]. Park et al [18] indicated that 15d-PGJ 2 and rosiglitazone independently of PPARγ inhibit the Janus kinase (JAK) signal transducer and activator of transcription (STAT) inflammatory signaling by reducing the phosphorylation of STAT1, STAT3, JAK1, and JAK2.…”